Increasingly, hospital and health systems have moved from paper charts to electronic health records (EHRs). EHRs offer ways to streamline clinical workflows, reduce medical errors and increase patient safety, and provide stronger support for clinical decision-making. However, linking such records from different locations for the same patient has proved problematic in many cases, leading to...
On January 12, the U.S. Food and Drug Administration approved Lynparza (olaparib), the PARP inhibitor partnered by AstraZeneca and Merck, for the treatment of BRCA-mutated, HER2-negative advanced metastatic breast cancer. The FDA’s action adds another cancer type for Lynparza; in late 2014 it was the first PARP inhibitor to be approved for use in...